You are here
A role for Apolipoprotein A-I in the pathogenesis of multiple sclerosis
Lindsay Meyers, Chassidy J. Groover, Joshua Douglas, Sangmin Lee, David Brand, Michael C. Levin, Lidia A. Gardner
Journal of Neuroimmunology, Volume 277, Issues 1–2, 15 December 2014, Pages 176–185
Apolipoprotein A1 (Apo A-I), the most abundant component of high-density lipoprotein (HDL), is an anti-inflammatory molecule, yet its potential role in the pathogenesis of multiple sclerosis (MS) has not been fully investigated. In this study, Western blot analyses of human plasma showed differential Apo A-I expression in healthy controls compared to MS patients. Further, primary progressive MS patients had less plasma Apo A-I than other forms of MS. Using experimental allergic encephalomyelitis (EAE) as a model for MS, Apo A-I deficient mice exhibited worse clinical disease and more neurodegeneration concurrent with increased levels of pro-inflammatory cytokines compared to wild-type animals. These data suggest that Apo A-I plays a role in the pathogenesis of EAE, a model for MS, creating the possibility for agents that increase Apo A-I levels as potential therapies for MS.